Tags : Esophageal Cancer

Almac Diagnostic Collaborates with Queen’s University to Bring Personalized Chemotherapy

Shots: Almac Diagnostic and Queen’s University validate a test to decide the chemotherapy to be used for early-stage esophageal cancer to remove the tumor, improve prognosis and QoL The focus of the collaboration is to bring personalized therapies for esophageal cancer. Additionally, Almac Diagnostic has developed DNA Damage Immune Response (DDIR) Signature to personalize chemotherapy […]Read More